Capricor Therapeutics Inc.
CAPR | NASDAQ
$9.40
+$0.50 (+5.62%)
Sep 22, 2026, 1:29 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 22.27M | 25.18M | 2.55M | 244.9K | 310.25K |
Cost of Revenue | n/a | 49.97M | 36.45M | 21.82M | n/a | n/a |
Gross Profit | n/a | -27.7M | -11.27M | -19.27M | 244.9K | 310.25K |
Operating Income | -108.14M | -42.56M | -24.08M | -29.7M | -20.94M | -13.69M |
Interest Income | 6.26M | 2.2M | 1.73M | 521.53K | n/a | n/a |
Pretax Income | -105.04M | -40.47M | -22.29M | -29.02M | -20.02M | -13.66M |
Net Income | -105.04M | -40.47M | -22.29M | -29.02M | -20.02M | -13.66M |
Selling & General & Admin | 22.75M | 14.87M | 12.81M | 10.43M | 7.61M | 5.54M |
Research & Development | 84.45M | 49.97M | 36.45M | 21.82M | 13.57M | 8.46M |
Other Expenses | 938.89K | -49.97M | -36.45M | -21.82M | n/a | n/a |
Operating Expenses | 108.14M | 14.87M | 12.81M | 10.43M | 21.18M | 14M |
Interest Expense | 3.05M | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 108.14M | 64.84M | 49.26M | 32.25M | 21.18M | 14M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 46.48M | 35.22M | 26.78M | 24.55M | 23.09M | 15.57M |
Shares Outstanding (Diluted) | 46.48M | 35.22M | 26.78M | 24.55M | 23.09M | 15.57M |
EPS (Basic) | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 |
EPS (Diluted) | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 |
EBITDA | -100.11M | -39.04M | -21.22M | -28.49M | -19.78M | -13.55M |
EBIT | -102M | -40.47M | -22.29M | -29.02M | -20.02M | -13.69M |
Depreciation & Amortization | 1.89M | 1.43M | 1.07M | 533.13K | 245.7K | 143.89K |
Add to Watchlist
Select watchlists to add or remove CAPR